The Global BCG Tuberculosis Vaccine Market size was US$ 63.58 million in 2022. The global market is expected to attain a market valuation of US$ 91.10 million by 2031, growing at a CAGR of 4.5% during the forecast period from 2023 to 2031.
The BCG tuberculosis market is experiencing a significant increase in revenue. This growth is primarily due to the increasing rates of tuberculosis cases. Factors such as a growing population, an increase in clinical trials, and the emphasis placed by governments and health authorities on immunization and the demand for the BCG vaccine to prevent childhood tuberculosis meningitis are also contributing to the global market’s expansion.
A Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/bcg-tuberculosis-vaccine-market
The global market is experiencing rapid growth driven by the increasing occurrence and prevalence of tuberculosis. There has been a significant surge in the number of TB-related deaths in recent years. For example, WHO reports that in 2021 alone, 1.6 million individuals died due to TB. TB is now the 13th leading cause of death worldwide, ranking second among infectious diseases after COVID-19 (surpassing HIV and AIDS). Furthermore, in 2021, the highest number of new TB cases was observed in WHO’s Southeast Asian Region (46%), followed by the African Region (23%) and the Western Pacific (18%). These escalating numbers highlight the urgent demand for the BCG vaccine, which, in turn, stimulates market growth.
The increasing population has a direct influence on the increasing demand for BCG tuberculosis vaccines. For instance, according to data from the United Nations, the global population is projected to grow by 2 billion people in the next 30 years, reaching 9.7 billion by 2050 from the current 7.7 billion. Consequently, the market for BCG TB vaccines is expanding owing to the high demand generated by the growing population.
Rising Clinical Trials: Unveiling New Opportunities for the Market Players
The bacille Calmette-Guérin (BCG) vaccine, which is used to treat tuberculosis (TB), is widely administered worldwide. With a history of nearly 100 years, it remains the only vaccine available for TB, a disease that affects over 10 million people annually.
Despite the age and widespread use of the BCG vaccine, there is still ongoing debate regarding its effectiveness in preventing tuberculosis (TB). This uncertainty surrounding its efficacy contributes to the increasing number of clinical trials being conducted, which, in turn, has the potential to boost the market for BCG TB vaccines.
For instance, in January 2023, the former director-general of the Council of Scientific & Industrial Research (CSIR) announced that clinical trials for a new BCG vaccine for tuberculosis will soon commence in India. The CSIR is actively working towards rapid diagnosis, vaccination, and treatment to eliminate tuberculosis from India by 2025, as per the government’s vision. These increasing clinical trials present significant growth opportunities for the market as they contribute to the development of new and improved BCG TB vaccines.
Hospitals Control More Than 50% of Market Revenue Share
Hospitals held a significant market share of 79.9% in 2022 and are anticipated to grow at a 4.7% CAGR from 2023 to 2031. The expansion of this market is due to the rising procurement and accessibility of vaccinations in hospital settings, as well as the rising delivery of the vaccine to newborns in hospitals.
The market is growing as a result of vaccinations becoming more widely available to patients and medical personnel in hospital settings. The administration and widespread usage of the BCG tuberculosis vaccination market on a global scale depend on hospitals, which are the main stakeholders in the healthcare system.
The hospital segment will continue to rule the market. The demand for BCG vaccines in hospital settings is anticipated to increase due to the continuous emphasis on baby immunization programs and the expanding global healthcare infrastructure.
Asia Pacific Captured Around 60% of the Global BCG Tuberculosis Vaccine Market
The Asia Pacific region generated revenue of US$ 41.02 million in 2022, and it is expected to reach a value of US$ 59.94 million by 2031. This region is projected to have the highest compound annual growth rate (CAGR) of 4.9% during the forecast period. This growth can be attributed to the presence of countries like Japan, Australia, and India, which place a strong emphasis on research and development activities. For instance, in March 2022, the Drugs Controller General of India received a request from the Serum Institute of India for Emergency Use Authorization (EUA) for its recombinant BCG (rBCG) vaccine for the treatment of tuberculosis.
The rising prevalence of tuberculosis in developing countries like China, Indonesia, and India is the main factor causing the Asia-Pacific area to expand. For instance, according to a June 2022 UNICEF report titled “Pediatric Tuberculosis with a Focus on Indonesia,” Indonesia has the second-highest TB incidence in the world (312 per 100,000 people) and is responsible for 8.5 percent of all cases worldwide.
For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/bcg-tuberculosis-vaccine-market
A quarter of all cases worldwide are caused by China, which after India has the second-highest burden of TB. A significant public health concern is the prevalence of TB in China. Approximately 900,000 new cases of TB are recorded annually, with the highest prevalence occurring in the Xinjiang Uygur autonomous region (184.5 cases per 100,000 inhabitants).
Top Players in the Global BCG Tuberculosis Vaccine Market
- Japan BCG Laboratory
- China Biotechnology Co., Ltd
- Merck KGaA
- Serum Institute of India Pvt. Ltd.
- GSBPL
- AJ Vaccines
- Statens Serum Institute
- Other Prominent players
Market Segmentation Outline
By Type
- Immune BCG
- Therapy BCG
By Application
- Hospital
- Clinics
By Region
- North America
-
- The U.S.
-
- Canada
-
- Mexico
- Europe
- Western Europe
-
-
- The UK
-
-
-
- Germany
-
-
-
- France
-
-
-
- Italy
-
-
-
- Spain
-
-
- Rest of Western Europe
- Eastern Europe
-
-
- Poland
-
-
-
- Russia
-
-
- Rest of Eastern Europe
- Asia Pacific
-
- China
-
- India
-
- Japan
-
- South Korea
-
- Australia & New Zealand
-
- ASEAN
-
- Rest of Asia Pacific
- Middle East & Africa
-
- UAE
-
- Saudi Arabia
-
- South Africa
-
- Rest of MEA
- South America
-
- Argentina
-
- Brazil
-
- Rest of South America
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/bcg-tuberculosis-vaccine-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐄𝐦𝐚𝐢𝐥: sales@astuteanalytica.com
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/